NCT05032950View on ClinicalTrials.gov

Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

December 9, 2021

Study Completion Date

December 9, 2021

Conditions
Healthy Participants
Interventions
DRUG

Midazolam

Midazolam administered as a single dose on Day 1

DRUG

PF-07321332/ritonavir + Midazolam

"PF-07321332/ritonavir:~Administered orally every 12 hours for a total of 9 doses on Days 1-5~Midazolam:~Administered orally as a single dose on Day 5"

DRUG

Ritonavir + Midazolam

"Ritonavir:~Administered orally every 12 hours for a total of 9 doses on Day1-5.~Midazolam:~Administered orally as a single dose on Day 5"

Trial Locations (1)

B-1070

Brussels Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05032950 - Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy Participants | Biotech Hunter | Biotech Hunter